Nippon Steel's share price rose by 1.2% shortly after the opening on Wednesday, and it is basically flat at present. In the news, US President Biden plans to formally prevent Nippon Steel from acquiring American steel companies for $14.1 billion. American steel stocks plunged overnight, once falling by 22%, and finally closed down by 9.7%.General Motors (GM): The unmanned business Cruise and GM Technical team will be merged, and the plan is expected to be completed in the first half of 2025. According to the priority of GM's capital allocation, GM will no longer fund Cruise's self-driving taxi development business.Japan's producer price in November increased by 0.3% month-on-month, and it is estimated to increase by 0.2%. Japan's producer price in November increased by 3.7% year-on-year, and it is estimated to increase by 3.4%.
New Zealand appoints WINSTON PETERS as Minister of Railways.Supervision intervened in the illegal use of self-built valuation models by financial subsidiaries. The reporter was informed that in view of the recent "self-built valuation model" prevalent in financial subsidiaries, the financial supervision department began to intervene and issued a notice requiring financial subsidiaries not to iron out the fluctuation of product net value through illegal closing price, smooth valuation and self-built valuation models. (21st century business herald)Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.
Vanke: It received a loan of 1.05 billion yuan from the Postal Savings Bank. On December 10th, Vanke Enterprise Co., Ltd. (Vanke A, 000002.SZ) issued an announcement on providing guarantee for bank loans. According to the announcement, Vanke recently applied for a loan from Shenzhen Luohu Sub-branch of Postal Savings Bank of China Co., Ltd. (hereinafter referred to as "Postal Savings Bank"), with a total loan principal of RMB 1.05 billion, and subsequent companies will make withdrawals according to business needs. The holding subsidiaries of the Company provide corresponding mortgage and pledge guarantee for the relevant loans respectively, and at the same time, the holding subsidiaries, as co-borrower, undertake repayment obligations together with the Company. After this guarantee, the total external guarantee of the company and its holding subsidiaries will be 118.673 billion yuan, accounting for 4.732% of the company's audited net assets attributable to shareholders of listed companies at the end of 2023.Goldman Sachs: I don't agree that gold can't reach $3,000 under a strong dollar. Goldman Sachs said that we don't agree with the view that the price of gold can't rise to $3,000 per ounce by the end of 2025 when the dollar remains strong for a long time. We predict that gold will reach $3,000 per ounce by the end of 2025, and the reduction of interest rate cuts by the Federal Reserve (rather than the strengthening of the US dollar) is the downside risk of this prediction.More support policies for specialization and innovation are brewing. According to the data of the Ministry of Industry and Information Technology, up to now, China has cultivated a total of 14,600 "little giant" enterprises with specialization and innovation, and more than 140,000 small and medium-sized enterprises with specialization and innovation. Over 80% of the "Little Giant" enterprises are located in strategic emerging industrial chains such as integrated circuits and aerospace, and the number of enterprises in future industry-related fields such as artificial intelligence and low-altitude economy is nearly 5,000. The reporter was informed that the relevant departments will study and formulate guidance on building a mechanism to promote the development and growth of specialized and innovative small and medium-sized enterprises, issue guidance on cultivating high-quality enterprises, continue to increase support for the cultivation of specialized and innovative small and medium-sized enterprises, and promote the "expansion, quality improvement and strong chain" of specialized and innovative groups. (Economic Information Daily)